Key result
Advanced glycation end products dose-dependently increase RAGE expression, ROS formation, and neutrophil-endothelial adhesion.
Why the study?
Do advanced glycation end products promote endothelial cell alterations in saphenous vein segments from diabetic patients with optimized glycemic control?
Do advanced glycation end products promote endothelial cell alterations in saphenous vein segments from diabetic patients with optimized glycemic control?
Elevated AGE levels promote pro-thrombotic endothelial alterations in saphenous veins even in diabetic patients with optimized glycemic control, potentially explaining increased graft failure.
No takes yet. Share an insight, caveat, or question.
AGEs may promote endothelial dysfunction in saphenous veins despite glycemic control; leaves open whether AGE modulation improves graft patency in diabetes.
Chello et al. (2009) studied Diabetic patients undergoing coronary surgery. Advanced glycation end products (AGEs) vs. Absence of AGEs was evaluated on Expression of RAGE and PPAR-gamma, ROS formation, and neutrophil-endothelial adhesion. Incubation of saphenous vein segments and endothelial cells with advanced glycation end products dose-dependently increased RAGE expression, ROS formation, and neutrophil-endothelial adhesion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: